美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

NETLease Corporate Real Estate ETF

25.63

+0.07040.28%

成交量：3,497

成交額：9.01萬

市值：4,933.78萬

市盈率：- -

高：25.82

開：25.81

低：25.63

收：25.56

52周最高：28.43

52周最低：23.56

股本：192.50萬

流通股本：192.50萬

量比：0.10

換手率：0.18%

股息：1.26

股息率：4.90%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

CRO板塊強勢走高！多家CRO上市公司解密業務近況

微博财经-财道工作室

數據中心熱潮重塑美國商業地產債市投資者面臨風險定價難題

Realty Income（O）攜手KKR（KKR）成立合資公司拓展歐洲優質淨租賃商業地產市場

DESTINY-Lung04 III期臨床研究顯示，優赫得®一線治療HER2突變晚期非小細胞肺癌患者的中位無進展生存期達14.3個月

Realty Income與KKR攜手共建歐元計價合資企業，助推Realty Income私募資本平台發展

18.5個月！這款國產藥刷新全球小細胞肺癌二線治療最長總生存期紀錄

富國銀行：SpaceX無線業務將衝擊傳統運營商，而鐵塔房地產投資信託基金將「悄然」獲利

环球市场播报

降息劇本反轉！8750億美元債務牆逼近美國商業地產又到危險時刻

FX168全球投资

一個還沒進臨床的分子，憑什麼賣出12.95億美元

【灣區早參】深圳啓動私募合規自查；8月廣州二手住宅市場網籤量按年微增

禮來上半年營收427.73億美元，替爾泊肽佔比65%近277億美元

经济参考网

Realty Income Corp與富國銀行達成5億美元定期貸款協議，2027年8月到期

藥明合聯 2026 年上半年業績：業務穩步推進，利潤率與盈利規模持續提升，夯實全球ADC/XDC CRDMO 領先地位

基石藥業-B(02616)：CS5007(EGFR/HER3雙特異性ADC)IND申請獲中國NMPA批准

燦芯股份發布28nm高性能SAR ADC IP

新加坡基地BCM3雙功能產線成功完成GMP放行，以專業實力賦能全球客户

阿斯利康(AZN.US)/第一三共ADC一線治療肺癌III期研究成功

百利天恒：雙抗ADC藥物非小細胞肺癌III期臨床達主要終點

博安生物(06955)：BA1302 (CD228 ADC)完成中國Ia期臨床研究

艾力斯醫藥獲得ArriVent潛在全球首創ADC權益；京東健康上半年累計首發65款新藥 | 醫藥早參

每日经济新闻

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/NETL/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NETL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NETL\",,,,,undefined,":{"symbol":"NETL","market":"US","secType":"STK","nameCN":"NETLease Corporate Real Estate ETF","latestPrice":25.63,"timestamp":1789405884660,"preClose":25.5596,"halted":0,"volume":3497,"delay":0,"changeRate":0.002754346703391264,"floatShares":1925000,"shares":1925000,"eps":0,"marketStatus":"交易中","change":0.0704,"latestTime":"09-14 13:13:34 EDT","open":25.81,"high":25.8199,"low":25.63,"amount":90076.33098099999,"amplitude":0.00743,"askPrice":25.72,"askSize":1,"bidPrice":25.5,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":25.5596,"sharesOutstanding":1775000,"nav":25.62,"aum":54442500,"dividendRate":0.048966,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.5785,"preClose":25.5596,"latestTime":"19:30 EDT","volume":11,"amount":281.1556,"timestamp":1789169405972,"change":0.0189,"changeRate":0.000739,"amplitude":0},"volumeRatio":0.100486,"impliedVol":0.1125,"impliedVolPercentile":0.2709},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NETL\",,,,,undefined,":{"symbol":"NETL","floatShares":1925000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.100486,"shares":1925000,"dividePrice":1.255,"high":25.8199,"amplitude":0.00743,"preClose":25.5596,"low":25.63,"week52Low":23.56,"pbRate":"--","week52High":28.4299,"institutionHeld":0,"latestPrice":25.63,"committee":0.980198,"eps":0,"divideRate":0.048966,"volume":3497,"delay":0,"ttmEps":0,"open":25.81,"prevYearClose":23.727,"prevWeekClose":25.5596,"prevMonthClose":26.1278,"prevQuarterClose":26.7001,"fiveDayClose":26.2,"twentyDayClose":26.6029,"sixtyDayClose":25.9677},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NETL\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"NETL","amount":0.105,"announcedDate":"2026-08-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-27","defaultRemindTime":1787837400000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-27","currency":"USD","dateTimestamp":1787803200000,"payDate":"2026-08-31"},{"date":"2026-07-29","symbol":"NETL","amount":0.105,"announcedDate":"2026-07-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-29","defaultRemindTime":1785331800000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-31","payableDate":"2026-07-29","currency":"USD","dateTimestamp":1785297600000,"payDate":"2026-07-31"},{"date":"2026-06-26","symbol":"NETL","amount":0.105,"announcedDate":"2026-06-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-26","defaultRemindTime":1782480600000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-26","currency":"USD","dateTimestamp":1782446400000,"payDate":"2026-06-30"},{"date":"2026-05-27","symbol":"NETL","amount":0.105,"announcedDate":"2026-05-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-27","defaultRemindTime":1779888600000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-29","payableDate":"2026-05-27","currency":"USD","dateTimestamp":1779854400000,"payDate":"2026-05-29"},{"date":"2026-04-28","symbol":"NETL","amount":0.105,"announcedDate":"2026-04-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-28","defaultRemindTime":1777383000000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-30","payableDate":"2026-04-28","currency":"USD","dateTimestamp":1777348800000,"payDate":"2026-04-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NETL\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-30","recordDate":"2019-12-31","paymentDate":"2020-01-02","value":0.031935,"currency":"USD"},{"executeDate":"2020-03-17","recordDate":"2020-03-18","paymentDate":"2020-03-19","value":0.0097783,"currency":"USD"},{"executeDate":"2020-03-31","recordDate":"2020-04-01","paymentDate":"2020-04-02","value":0.1912399,"currency":"USD"},{"executeDate":"2020-06-26","recordDate":"2020-06-29","paymentDate":"2020-06-30","value":0.2782635,"currency":"USD"},{"executeDate":"2020-09-15","recordDate":"2020-09-16","paymentDate":"2020-09-30","value":0.2792338,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NETL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NETL\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667466104","title":"CRO板塊強勢走高！多家CRO上市公司解密業務近況","url":"https://stock-news.laohu8.com/highlight/detail?id=2667466104","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667466104?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 21:08","pubTimestamp":1789391280,"startTime":"0","endTime":"0","summary":"在互动平台与机构调研中，多家具备CRO业务的上市公司近期密集回应市场关切，披露了订单、产能及全球化布局的最新进展。2026 年上半年，公司实现 CRO 销售收入 4,513.95 万元， 较上年同期增长 10.91%。截至 2026 年上半年末，客户群体不断扩大，累计服务超过 16,900 家研发实验室客户。CRO 业务毛利率基本保持相对稳定水平，具体受服务类型、项目内容影响有所波动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-09-14/doc-inirveaq9305051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ADC","BK4231","MEDX","BK1574","NETL","LNGR","IBBQ","BK1161","06978","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637326","title":"數據中心熱潮重塑美國商業地產債市 投資者面臨風險定價難題","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637326","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667637326?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:43","pubTimestamp":1789386232,"startTime":"0","endTime":"0","summary":"如今，这一市场正被汹涌而至的数据中心交易重塑，投资者不得不直面一系列全新风险。数据中心发债潮来袭，风险评估成难题自2025年初以来，数据中心CMBS发行规模已达约170亿美元，是此前两年发行总额的三倍以上。在此期间，数据中心已占新增商业地产债券约8%的比重。考虑到后续还有数十亿美元项目排队入场，业内资深人士正在迅速修订风险评估手册，以期避开爆雷项目。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IWN","PPTY","DFGR","HPEL","WISE","ICF","AREA","IJR","FRI","USRT","JPSE","NETL","CAAA","REK","CLOU","BPRE","TSRS","FNK","RDOG","IDGT","FMET","BSMC","ISCB","XHOA","DCMB","FCLD","BLOK","SCDV","BBRE","CLDL","HHH","AIO","DCRE","03141","PBOT","RIET","RNIN","CMBS","DTCR","RWR","DESK","WDAI","RZV","EBIT","VBR","REIT","DFAT","WPAI","AIFD","AIBU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668218","title":"Realty Income（O）攜手KKR（KKR）成立合資公司 拓展歐洲優質淨租賃商業地產市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668218","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668218?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:28","pubTimestamp":1789385311,"startTime":"0","endTime":"0","summary":"根据协议，KKR管理的资本账户将出资5.28亿欧元，收购该合资公司49%的股权；Realty Income将保留51%的控股权，并通过其欧洲运营平台继续负责资产的日常运营与管理。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306000","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HAUZ","IQRA","TRUR","JRE","IRET","NETL","GQRE","DVRE","VGSR","KKR","FPRO","IYRI","CRIB","SRET","REAI","BYRE","SRHR","DRW","URE","AVRE","ERET","FREL","AAUM","NRO","GRI","RINC","DFAR","ACVU","PRVT","O","SRS","RNTY","HIPS","RWO","CLIM","LBO","KBWY","PSP","LPRE","GPZ","DPRE","PSR","RWR","CSRE","JPRE","RSPR","FREI","DFGR","BLDG","XLRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667645276","title":"DESTINY-Lung04 III期臨床研究顯示，優赫得®一線治療HER2突變晚期非小細胞肺癌患者的中位無進展生存期達14.3個月","url":"https://stock-news.laohu8.com/highlight/detail?id=2667645276","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667645276?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:16","pubTimestamp":1789384560,"startTime":"0","endTime":"0","summary":"德曲妥珠单抗组的中位PFS为14.3个月，而帕博利珠单抗联合化疗组为8.3个月。\" 阿斯利康全球执行副总裁、肿瘤研发负责人Susan Galbraith表示：\"DESTINY-Lung04是首项在HER2突变晚期NSCLC患者中，证实PFS优于全球一线标准治疗的III期临床研究。在DESTINY-Lung04临床研究中，德曲妥珠单抗的安全性特征与其已知安全谱总体一致，未发现新的安全性问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5046853_ZH46853_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5046853_ZH46853_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0320765992.SGD","LU1267930573.SGD","IE00B19Z4B17.USD","DCO","IE00B7SZL793.SGD","LU0128525929.USD","CR","LU1829250122.USD","BK4588","BK4161","LU1559883803.SGD","NETL","BK4568","LU2456880835.USD","ADC","PR","IE00B3T34201.USD","LU0708994859.HKD","ORR","LU0109394709.USD","PFS","LU2237443895.HKD","IE00B66KJ199.SGD","BK4211","LU2089984988.USD","LU2236285917.USD","IE0031619046.USD","LU0432979614.USD","BK4213","LU2237443978.SGD","ROKT","BK4195","LU2417539215.USD","LU2237443465.HKD","LU0566484027.USD","FXN","LU2462157665.USD","AZN","LU0310800379.SGD","BK4007","AZNH","LU2237443622.USD","LU2237443549.SGD","BK4585","LU0289739699.SGD","PXI","BK4187","LU0058720904.USD","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118491492","title":"Realty Income與KKR攜手共建歐元計價合資企業，助推Realty Income私募資本平台發展","url":"https://stock-news.laohu8.com/highlight/detail?id=1118491492","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118491492?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:01","pubTimestamp":1789383678,"startTime":"0","endTime":"0","summary":"Realty Income与KKR宣布，双方将共同设立一个以欧元计价的合资企业。此举标志着Realty Income在私募资本领域的布局迈出了关键一步，为其平台注入了新的增长动力。此番合作不仅拓宽了融资渠道，更彰显了Realty Income致力于拓展欧洲市场、深化机构合作伙伴关系的战略雄心。通过这一合资架构，Realty Income有望进一步优化资本配置，强化其在全球房地产投资领域的竞争力，同时也为KKR提供了切入优质资产组合的契机。双方强强联手，预示着在复杂多变的全球资本市场中，一场由资本实体与专业管理能力深度融合的新篇章已然开启。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DPRE","ERET","LU0314104364.USD","BK4135","DFAR","PSP","LU0106831901.USD","LU1935043023.USD","LU1668664300.SGD","BK4080","LBO","NETL","LU0648001328.SGD","LU0980610538.SGD","GPZ","RWR","LU1935043536.SGD","TSRS","CLIM","O","LU1935042488.USD","AAUM","LU0130102774.USD","IE00BGHQF748.EUR","PRVT","LU1935042215.USD","BK4588","LU1201861249.SGD","BK4585","KKR","IE00B3QW5Z07.USD","LU1935042991.SGD","LU1791807156.HKD","IE00B64PRP62.GBP","BK4231","SRHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667865276","title":"18.5個月！這款國產藥刷新全球小細胞肺癌二線治療最長總生存期紀錄","url":"https://stock-news.laohu8.com/highlight/detail?id=2667865276","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667865276?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 12:36","pubTimestamp":1789274208,"startTime":"0","endTime":"0","summary":"【18.5个月！这款国产药刷新全球小细胞肺癌二线治疗最长总生存期纪录】9月13日，在2026世界肺癌大会首日上午首场主席论坛上，翰森制药（03692.HK）自主研发的B7-H3靶向ADC——瑞康立伏妥塔单抗（研发代号：HS-20093），以最新突破性摘要形式亮相并作口头报告。这次公布的数据，瑞康立伏妥塔单抗刷新了小细胞肺癌（SCLC）二线治疗最长总生存期（OS）纪录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609133872794256.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609133872794256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["L","BK4107","BK4585","BK4588","LU0053666078.USD","LU2487616109.SGD","BK4211","BK1583","BK4080","BK1589","LU0210528500.USD","NETL","BK4231","BK1191","03692","ADC","BK4195","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666459784","title":"富國銀行：SpaceX無線業務將衝擊傳統運營商，而鐵塔房地產投資信託基金將「悄然」獲利","url":"https://stock-news.laohu8.com/highlight/detail?id=2666459784","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666459784?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 00:34","pubTimestamp":1789058040,"startTime":"0","endTime":"0","summary":"SpaceX 采用家庭微基站 + 屋顶终端的技术路线，所需地面基础设施远少于传统运营商，这也是铁塔、有线电视行业的潜在利好未必能够完全兑现的关键原因。关于 “第四大运营商” 的市场争论，卡哈尔的观点卡哈尔跳出了市场把 SpaceX 视作传统第四大运营商的固有分析框架。SpaceX 二季度通信业务收入达到 42.9 亿美元，同比上涨 66%。反观传统运营商，威瑞森固定无线业务净增用户同比下滑 30.6%，这是卫星宽带抢占市场的首个显性信号。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-11/doc-inirkiyn7472560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SPCX","MARS","RWO","WSPC","KBWD","MDIV","DFRA","VRAI","NETL","DPRE","WARP","SPCQ","SPHD","UFO","DTRE","SPCF","SPCU","ORBX","ALTY","RNTY","CSRE","GRI","DXYZ","REAI","SPCH","SPAL","IQRA","GARA","XOVR","AVRE","SPRE","IDGT","FPRO","ABLD","JPRE","HIPS","SNK","FREI","LOFF","VGSR","LOFD","XSHD","IVRA","BLDG","ASET","PGF","CRIB","INDS","IYLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665466493","title":"降息劇本反轉！8750億美元債務牆逼近 美國商業地產又到危險時刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2665466493","media":"FX168全球投资","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665466493?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 09:32","pubTimestamp":1788831122,"startTime":"0","endTime":"0","summary":"今年约有8750亿美元商业抵押贷款集中到期，其中相当一部分债务是在利率只有当前水平大约一半时发放。降息剧本反转，加息重新进入视野今年年初，商业地产市场普遍押注利率将逐步下降。挪威规模约2.3万亿美元的主权财富基金提出削减约800亿美元美国国债持仓。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2026/09/08093258377978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["SCDV","CAAA","FRI","DFGR","ICF","IJR","DCRE","CRED","NETL","RWR","PPTY","SCYB","BK4581","DFAT","RZV","BK4024","PEX","BPRE","RIET","BSMC","DCMB","RNIN","RDOG","CMBS","USRT","VBR","FNK","BBRE","BK4588","HHH","IWN","AREA","REK","BK4585","XHOA","DESK","ISCB","EBIT","JPSE","REIT","TSRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665062393","title":"一個還沒進臨床的分子，憑什麼賣出12.95億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665062393","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665062393?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 10:08","pubTimestamp":1788746914,"startTime":"0","endTime":"0","summary":"对一款尚未进入人体临床试验的资产而言，1.1亿美元的首付款属于明显偏高的定价。2023年，和黄医药将已在中国获批上市的呋喹替尼授权给武田制药：总额11.3亿美元，首付款4亿美元。那是\"成熟产品出海\"的典范，一个经过临床验证、获批上市的分子，换取全球市场权益。HMPL-A830尚未启动I期临床，和黄医药卖的是一个\"概念验证前\"的平台资产，而12.95亿美元的总交易额，已经超过了呋喹替尼的11.3亿美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788491648644278418","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1588","BK4231","BK1191","NETL","00013","KURE","BK1587","ADC","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664847227","title":"【灣區早參】深圳啓動私募合規自查；8月廣州二手住宅市場網籤量按年微增","url":"https://stock-news.laohu8.com/highlight/detail?id=2664847227","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664847227?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 08:42","pubTimestamp":1788396159,"startTime":"0","endTime":"0","summary":"3、深圳启动私募合规自查深圳证监局近日下发通知，启动2026年深圳辖区私募投资基金合规自查工作。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990487","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","IE00B543WZ88.USD","BK4211","BK1574","LU0634319403.HKD","BK1161","LU2476274720.SGD","BK4080","BK4195","LU0348825331.USD","ADC","LU1961090484.USD","BK1589","LU0417516738.SGD","NETL","LU0348766576.USD","LU0348783233.USD","LU2778985437.USD","BK1227","BK1163","KURE","LU0540923850.HKD","LU0561508036.HKD","BK4231","BK1583","IPOS","LU0348827113.USD","LU1720050803.USD","PFS","LU2488822045.USD","LU2476274308.USD","LU0417516902.SGD","LU2399975544.HKD","00933","IE00B5MMRT66.SGD","LU0348784397.USD","LU1794554557.SGD","BK1191","LU0348735423.USD","IE00BPRC5H50.USD","03310","LU0417516571.SGD","LU0348767384.USD","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663046879","title":"禮來上半年營收427.73億美元，替爾泊肽佔比65%近277億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2663046879","media":"经济参考网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663046879?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 12:16","pubTimestamp":1788063391,"startTime":"0","endTime":"0","summary":"近日，礼来（EliLillyandCompany，NYSE：LLY）公布2026年上半年及第二季度业绩。财报显示，今年上半年，礼来实现总营收427.73亿美元，同比增长49%。其中第二季度营收达229.74亿美元，同比增长48%，超市场预期。基于上半年的强劲增长势头，礼来将2026年全年营收指引从此前的820亿至850亿美元上调至850亿至870亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608303859354883.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608303859354883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01801","LU0326950275.SGD","LU0244354667.USD","LU2097828631.EUR","LU0455707207.USD","LU2097828474.EUR","BK1583","NETL","BK1161","LU2097828805.USD","LU2242644610.SGD","BK4230","ADC","LU1188198961.HKD","LU1969619763.USD","LU0502904849.HKD","BK4080","LU0463099449.HKD","BK1589","LU2097828557.USD","HK0000165453.HKD","BK4022","KURE","BK4231","LU2097828714.EUR","LU2488822045.USD","LU2328871848.SGD","CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113124215","title":"Realty Income Corp與富國銀行達成5億美元定期貸款協議，2027年8月到期","url":"https://stock-news.laohu8.com/highlight/detail?id=1113124215","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113124215?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 04:09","pubTimestamp":1787688550,"startTime":"0","endTime":"0","summary":"Realty Income Corp已与富国银行签订定期贷款协议。根据美国证券交易委员会的文件显示，此项协议涉及一笔总额达5亿美元的定期贷款，该贷款将于2027年8月20日到期。这一融资安排标志着Realty Income在资本管理领域的又一重要举措。市场分析人士指出，该贷款期限适中，利率条件具有竞争力，反映了Realty Income在信贷市场中良好的信誉和谈判实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4588","BK4231","NETL","RWR","TSRS","SRHR","DFAR","CLIM","ERET","BK4585","O","DPRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662438270","title":"藥明合聯 2026 年上半年業績：業務穩步推進，利潤率與盈利規模持續提升，夯實全球ADC/XDC  CRDMO 領先地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2662438270","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662438270?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 20:35","pubTimestamp":1787574900,"startTime":"0","endTime":"0","summary":"毛利及毛利率  2026年上半年，本集团毛利同比增长40.6%至13.71亿元人民币，毛利率为37.0%，较2025年上半年提升0.9个百分点。经调整归属母公司净利润及其利润率  2026年上半年，经调整归属母公司净利润同比增长37.4%，至10.27亿元人民币，彰显了本集团核心经营业务强劲的利润增长势头。2026年上半年客户和项目亮点  本集团持续扩大客户群，累计客户数达814家。值得注意的是，截至报告期末，本集团累计完成超过22,000个ADC/XDC分子的研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5032132_ZH32132_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5032132_ZH32132_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["02268","BK1141","SG9999014674.SGD","LU2488822045.USD","BK4080","BK4231","NETL","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661306402","title":"基石藥業-B(02616)：CS5007(EGFR/HER3雙特異性ADC)IND申請獲中國NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2661306402","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661306402?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 06:08","pubTimestamp":1787263715,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司管线2.0核心候选药物之一CS5007的新药临床试验申请，已通过中国国家药品监督管理局创新药临床试验审评审批通道快速获得批准，全程仅用23个工作日。此前，CS5007的全球多中心I期临床试验已于2026年6月在澳大利亚启动并完成首例患者入组，该项试验也将同步在中国开展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483000.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","ADC","BK4231","BK4080","BK1574","02616","BK1161","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660407386","title":"燦芯股份發布28nm高性能SAR ADC IP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660407386","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660407386?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 16:51","pubTimestamp":1787215892,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2463526074.USD","LU1169589451.USD","BK4080","ADC","BK4136","IP","BK4135","SAR","NETL","LU1487256676.USD","WOOD","LU1481599808.USD","CUT","LU1481600234.SGD","IE00B3T34201.USD","BK4585","LU1169590202.USD","BK4588","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660307451","title":"新加坡基地BCM3雙功能產線成功完成GMP放行，以專業實力賦能全球客户","url":"https://stock-news.laohu8.com/highlight/detail?id=2660307451","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660307451?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 11:59","pubTimestamp":1787025540,"startTime":"0","endTime":"0","summary":"药明合联新加坡基地BCM3双功能产线成功实现GMP放行  作为公司海外首个通过GMP放行的产能设施，BCM3产线采用高效灵活的\"双功能\"设计理念，提供从抗体中间体到偶联原液的全流程一站式商业化生产服务。根据新加坡基地后续产线建设规划，其制剂生产线DP4亦将于2026年8月底完成GMP放行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5028415_ZH28415_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5028415_ZH28415_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1141","02268","NETL","ADC","LU2488822045.USD","BK4080","SG9999014674.SGD","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660248062","title":"阿斯利康(AZN.US)/第一三共ADC一線治療肺癌III期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2660248062","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660248062?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 20:44","pubTimestamp":1786970699,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月17日，阿斯利康和第一三共联合宣布Enhertu单药一线治疗非小细胞肺癌的III期DESTINY-Lung04研究取得了高水平的积极结果。结果显示，Enhertu组患者的PFS较标准治疗组实现了统计学显著且临床意义显著的改善。值得一提的是，Enhertu是第一个在III期研究中成功证明单药相较标准治疗作为一线治疗方案能够改善NSCLC患者的PFS的ADC药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0310800379.SGD","LU0889565916.HKD","LU0109394709.USD","AZNH","IE00B3T34201.USD","LU2417539215.USD","BK4007","BK4080","LU1267930573.SGD","LU0058720904.USD","III","LU2468319806.SGD","LU2089984988.USD","ADC","BK4588","LU0320765992.SGD","LU0029864427.USD","NETL","LU2462157665.USD","LU0289739699.SGD","LU1829250122.USD","LU2236285917.USD","LU0432979614.USD","LU0708994859.HKD","LU2237443622.USD","BK4231","LU2237443978.SGD","BK4568","LU2237443465.HKD","LU2237443895.HKD","LU0128525929.USD","LU2237443382.USD","AZN","LU2456880835.USD","LU2237443549.SGD","BK4585","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660486161","title":"百利天恒：雙抗ADC藥物非小細胞肺癌III期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2660486161","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660486161?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:34","pubTimestamp":1786959283,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4080","NETL","ADC","III","BK4231","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659147909","title":"博安生物(06955)：BA1302 (CD228 ADC)完成中國Ia期臨床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2659147909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659147909?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 22:22","pubTimestamp":1786717377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 发布公告，公司自主研发的靶向CD228的创新抗体偶联药物BA1302已完成中国I期临床研究单药剂量递增阶段(Ia期)。研究结果显示，BA1302在经多线治疗后疾病仍进展的多种晚期实体瘤患者中展现出良好的抗肿瘤活性，整体安全耐受性良好。据公司所知，BA1302是目前全球唯一处于临床阶段的靶向CD228 ADC。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NETL","ADC","06955","BK1161","BK4080","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659618195","title":"艾力斯醫藥獲得ArriVent潛在全球首創ADC權益；京東健康上半年累計首發65款新藥 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2659618195","media":"每日经济新闻","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659618195?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 07:01","pubTimestamp":1786662085,"startTime":"0","endTime":"0","summary":"丨2026年8月14日星期五丨NO.1艾力斯医药获得ArriVent潜在全球首创ADC权益8月13日，艾力斯宣布与ArriVentBioPharma,Inc.(ArriVent)签署战略合作协议，公司获得在中国研究、开发、生产、注册以及商业化抗体偶联药物（ADC）AST12608/ARR-002的独占许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608143840884969.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608143840884969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","LU0456827905.SGD","BK1574","SGXZ86797644.SGD","BK1142","BK4231","ADC","NETL","86618","09939","SGXZ62798434.SGD","BK0239","BK1515","06618","688578","BK1571","BK1161","LU0051755006.USD","BK1583","BK1589","BK1615","BK1591","159938","BK1247"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":61,"code":"91000000","status":"200"}]}}